Compare Novavax Inc (NVAX) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs UiPath Inc — how do they compare? Novavax Inc trades at $7.92 (market cap $1.31B), while UiPath Inc trades at $15.66 (market cap $8.14B). The key difference: UiPath Inc is far larger — about 6.2× Novavax Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | PATH | |
|---|---|---|
Market Cap | $1.31B | $8.14B |
Sector | Health | Technology |
52-Week High | $11.19 | $19.29 |
52-Week Low | $6.22 | $9.38 |
Enterprise Value | $889.30M | $6.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
UiPath (PATH) trades at $15.32, down 1.73% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company shows strong revenue growth, improving from $1.43B in 2025 to a projected $1.7B in 2026, and achieved profitability in recent quarters. Recent news highlights institutional buying and AI-driven stock rallies, though earnings volatility remains a concern.
Outlook is cautiously optimistic with a consensus price target of $13.33, below the current price, indicating potential downside. Risks include competitive pressures in AI automation and earnings misses, but improving margins and institutional interest offer upside if execution strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
